Oncology Institute (TOI) director receives 25,833 fully vested RSU shares

Rhea-AI Filing Summary

STOLPER MARK reported acquisition or exercise transactions in this Form 4 filing.

Oncology Institute, Inc. director Mark Stolper reported an equity compensation grant of 25,833 shares of Common Stock on July 7, 2026. The Form 4 classifies this as a grant or award (code A) at a stated price of $0.00 per share, reflecting a non-cash award. A footnote explains that the grant represents an RSU award that was fully vested upon grant. Following this transaction, Stolper directly owns 25,833 shares of Oncology Institute common stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider STOLPER MARK

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	25,833	$0.00	--

Holdings After Transaction: Common Stock — 25,833 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares granted: 25,833 shares Transaction price per share: $0.00 per share Shares owned after transaction: 25,833 shares +1 more

4 metrics

Shares granted 25,833 shares RSU award of Common Stock on July 7, 2026

Transaction price per share $0.00 per share Reported price for RSU grant (non-cash award)

Shares owned after transaction 25,833 shares Direct holdings following RSU grant

Transaction date July 7, 2026 Grant date for RSU award

Key Terms

RSU, Grant, award, or other acquisition, Common Stock, Form 4

4 terms

RSU financial

"Represents RSU award that was fully vested upon grant."

Restricted stock units (RSUs) are a form of company shares given to employees as part of their compensation, usually with certain restrictions or conditions, such as remaining with the company for a set period. When these restrictions lift, employees receive actual shares that they can sell or hold. For investors, RSUs can impact a company's stock supply and reflect the company's commitment to attracting and retaining talent.

Grant, award, or other acquisition financial

"transaction code description is "Grant, award, or other acquisition" for this entry."

Common Stock financial

"The security title for this transaction is listed as Common Stock."

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/09/2026 - 04:30 PM Accepted by SEC EDGAR 07/09/2026 - 04:30 PM Learn about SEC filing dates

FAQ

What insider transaction did Oncology Institute (TOI) director Mark Stolper report?

Mark Stolper reported receiving an equity grant of 25,833 shares of Oncology Institute common stock. The Form 4 labels this as a grant or award, indicating compensation rather than an open-market purchase, and all shares were fully vested at the time of grant.

How many Oncology Institute (TOI) shares were granted to Mark Stolper and at what price?

Stolper received 25,833 shares of Oncology Institute common stock at a reported transaction price of $0.00 per share. This reflects a stock-based compensation award, not a cash purchase, with the value determined separately from a market trade.

Were Mark Stolper’s Oncology Institute (TOI) RSUs vested immediately?

Yes, the footnote explains the award represents an RSU grant that was fully vested upon grant. This means Stolper’s rights to all 25,833 shares were not subject to further vesting conditions as of the grant date.

Is Mark Stolper’s Oncology Institute (TOI) transaction a buy or a compensation grant?

The Form 4 characterizes the transaction as a grant or award acquisition with code A, not an open-market buy. Stolper acquired 25,833 shares as stock-based compensation, rather than purchasing shares on the open market.

What are Mark Stolper’s Oncology Institute (TOI) holdings after this RSU grant?

After the reported transaction, Stolper directly holds 25,833 shares of Oncology Institute common stock. The filing does not show additional derivative positions, so this figure reflects his post-transaction direct equity stake disclosed in this Form 4.

What does transaction code A mean in Mark Stolper’s Oncology Institute (TOI) Form 4?

Transaction code A indicates a grant, award, or other acquisition of securities. In this case, Stolper received 25,833 fully vested RSU shares as compensation, rather than through a market trade or option exercise.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

STOLPER MARK

(Last) (First) (Middle)

18000 STUDEBAKER ROAD, SUITE 800

(Street)

CERRITOS CALIFORNIA 90703

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Oncology Institute, Inc. [ TOI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/07/2026		A(1)		25,833	A	$0.00	25,833	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents RSU award that was fully vested upon grant.

	/s/ Mark Hueppelsheuser, Attorney-in-fact for Mark Stolper	07/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)